Category Business

MERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA

MERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and…

Read MoreMERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a new partnership with Alnylam to develop and commercialise zilebesiran, an…

Read MoreRoche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs

Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) today announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of…

Read MoreFlagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030…

Read MoreAstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development…

Read MoreGilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine

AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine AbbVie (NYSE: ABBV) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the…

Read MoreAbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine

Bayer extends partnership with Peking University to foster pharmaceutical innovation in China

Bayer extends partnership with Peking University to foster pharmaceutical innovation in China Bayer and Peking University (PKU) will collaborate to foster the translation of basic pharmaceutical research into drug discovery and development, while accelerating scientific research on cutting-edge technologies across…

Read MoreBayer extends partnership with Peking University to foster pharmaceutical innovation in China

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030…

Read MoreAstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata

FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age…

Read MoreFDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata

WHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change

WHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change WHO and international advocacy organization Global Citizen today signed a memorandum of understanding to collaborate on joint global advocacy initiatives aimed…

Read MoreWHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change